Biohaven (BHVN)

• Market cap: $1.51B
• 1 day: -3.24%
• 5 days: -0.09%
• 1 month: 7.78%
• 3 months: -25.95%
• 6 months: -18.51%
• Year to date: 4.8%
• 1 year: -71%
• 5 years: 59.1%
• 10 years: 59.1%
• Sector: Healthcare
• Industry: Biotechnology

About: Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

Employees: 256